Understanding FDA’s Draft Guidance on Cancer Clinical Trial Eligibility Criteria: Performance Status

The FDA's draft guidance marks a significant step toward more inclusive and relevant cancer clinical trials. Aimed at industry stakeholders, IRBs, and clinical investigators, this document highlights the need to…

Continue ReadingUnderstanding FDA’s Draft Guidance on Cancer Clinical Trial Eligibility Criteria: Performance Status